They include Pinometostat (EPZ-5676), an inhibitor of DOT1L, and Tazemetostat (EPZ-6438), an inhibitor of EZH2, which are being investigated for the treatment of AML, MM, and MDS [25]. Here, EZH2 is linked to myelodysplastic syndrome.